Samjin Pharmaceuticals Co., Ltd. (KRX:005500)

Market Cap	241.72B -0.2%
Revenue (ttm)	274.03B +45.0%
Net Income	21.89B +49.0%
EPS	1,727.82 +52.0%
Shares Out	12.26M
PE Ratio	11.41
Forward PE	10.39
Dividend	800.00 (4.06%)
Ex-Dividend Date	Dec 29, 2025

Volume	104,535
Open	19,620
Previous Close	19,810
Day's Range	19,560 - 20,500
52-Week Range	16,580 - 25,900
Beta	0.19
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Samjin Pharmaceuticals

Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also develops SA001, which is in Phase II clinical trial for the treatment for dry eye syndrome and Sjogren syndrome; SJP1804 medicine that is Phase I clin...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1968
• Employees: 586
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 005500

Financial Performance

In 2022, Samjin Pharmaceuticals's revenue was 274.03 billion, an increase of 9.58% compared to the previous year's 250.07 billion. Earnings were 21.89 billion, a decrease of -22.92%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 13, 2026

Data Sources Report a data error